Droxidopa vs Midodrine for Orthostatic Hypotension
Both droxidopa and midodrine are FDA-approved for treating orthostatic hypotension, with midodrine being the preferred first-line pharmacologic agent due to its established efficacy and safety profile. 1
Comparison of Medications
Mechanism of Action
- Midodrine: Alpha-1 adrenergic agonist that causes peripheral vasoconstriction 1
- Droxidopa: Synthetic amino acid that converts to norepinephrine, increasing blood pressure 1
Dosing
Midodrine: 10 mg up to 2-4 times daily 1
Droxidopa: 100-600 mg three times daily, with last dose at least 4 hours before bedtime 1
Efficacy
Midodrine has been shown to:
Droxidopa is specifically FDA-approved for neurogenic orthostatic hypotension 1
Treatment Algorithm
Start with non-pharmacological approaches:
- Physical counter-pressure maneuvers
- Compression garments
- Increased salt and fluid intake
- Small frequent meals
- Elevating head of bed during sleep
- Regular exercise to prevent deconditioning 1
If non-pharmacological measures are insufficient, initiate pharmacological therapy:
- First-line: Midodrine 10 mg three times daily
- Monitor for efficacy and adjust dosage as needed (2.5-10 mg per dose)
- Ensure last dose is taken at least 4 hours before bedtime
Consider droxidopa if:
- Patient has neurogenic orthostatic hypotension
- Inadequate response to midodrine
- Intolerable side effects with midodrine
Side Effects and Precautions
Midodrine
- Most common side effects: piloerection, pruritus, paresthesias, urinary retention, and chills 3
- Risk of supine hypertension (up to 25% of patients) 3
- Generally well-tolerated with mild adverse effects that can be controlled by reducing dosage 6
Both Medications
- Monitor for supine hypertension
- Regular blood pressure measurements in both supine and standing positions
- Avoid medications that can worsen orthostatic hypotension (opioids, anticholinergics, tricyclic antidepressants) 1
Clinical Pearls
- The therapeutic goal is to minimize postural symptoms rather than to restore normotension 7, 1
- Regular follow-up every 3 months once stabilized is recommended 1
- Patient education about recognizing prodromal symptoms is important for preventing episodes 1
- Midodrine has been shown to be at least as effective as other sympathomimetic agents with fewer and less severe adverse effects 6